

ESM Table 1. Fasting and Postprandial Glucose Concentrations in Study 3^a

	SITA 100	CANA 300
	(n = 61)	(n = 74)
FPG, mmol/l		
Baseline	8.6 (2.6)	8.5 (1.9)
Week 52	8.0 (2.0)	6.9 (1.6)
Change from baseline	-0.57 (2.64)	-1.64 (2.05)
Δ LSM (95% CI) ^b	—	-1.13 (-0.54; -1.72)
<i>p</i> value ^c	—	0.0002
MPG_{0-3h}, mmol/l		
Baseline	14.4 (3.0)	14.2 (2.8)
Week 52	12.6 (2.8)	11.1 (2.2)
Change from baseline	-1.80 (2.90)	-3.13 (2.90)
Δ LSM (95% CI) ^b	—	-1.52 (-0.75; -2.30)
<i>p</i> value ^c	—	0.0002
Maximum PG, mmol/l		
Baseline	17.4 (3.4)	17.2 (3.6)
Week 52	15.4 (3.4)	13.7 (3.0)
Change from baseline	-2.0 (3.3)	-3.5 (3.7)
Δ LSM (95% CI) ^b	—	-1.71 (-2.69; -0.74)
<i>p</i> value ^c	—	0.0007

CANA 300, canagliflozin 300 mg; SITA 100, sitagliptin 100 mg.

^aData are mean (SD) unless otherwise indicated.

^b Δ LSM is the SITA-subtracted LSM change from baseline.

^c*p* value vs SITA at Week 52.